<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">68542</article-id><article-id pub-id-type="doi">10.7554/eLife.68542</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>Heparin-binding motif mutations of human diamine oxidase allow the development of a first-in-class histamine-degrading biopharmaceutical</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-231100"><name><surname>Gludovacz</surname><given-names>Elisabeth</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-235445"><name><surname>Schuetzenberger</surname><given-names>Kornelia</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-233770"><name><surname>Resch</surname><given-names>Marlene</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-233771"><name><surname>Tillmann</surname><given-names>Katharina</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-233772"><name><surname>Petroczi</surname><given-names>Karin</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-176018"><name><surname>Schosserer</surname><given-names>Markus</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2025-0739</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-233773"><name><surname>Vondra</surname><given-names>Sigrid</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-233774"><name><surname>Vakal</surname><given-names>Serhii</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-233775"><name><surname>Klanert</surname><given-names>Gerald</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-89008"><name><surname>Pollheimer</surname><given-names>Jürgen</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8440-5221</contrib-id><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-233776"><name><surname>Salminen</surname><given-names>Tiina A</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-233777"><name><surname>Jilma</surname><given-names>Bernd</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-233778"><name><surname>Borth</surname><given-names>Nicole</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" corresp="yes" id="author-233779"><name><surname>Boehm</surname><given-names>Thomas</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8294-0797</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="fn" rid="conf5"/></contrib><aff id="aff1"><institution content-type="dept">Department of Biotechnology</institution>, <institution>Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna</institution>, <addr-line><named-content content-type="city">Vienna</named-content></addr-line>, <country>Austria</country></aff><aff id="aff2"><institution content-type="dept">Center for Medical Physics and Biomedical Engineering</institution>, <institution>Center for Medical Physics and Biomedical Engineering, Medical University of Vienna</institution>, <addr-line><named-content content-type="city">Vienna</named-content></addr-line>, <country>Austria</country></aff><aff id="aff3"><institution content-type="dept">Department of Clinical Pharmacology</institution>, <institution>Department of Clinical Pharmacology, Medical University of Vienna</institution>, <addr-line><named-content content-type="city">Vienna</named-content></addr-line>, <country>Austria</country></aff><aff id="aff4"><institution content-type="dept">Center for Biomedical Research</institution>, <institution>Center for Biomedical Research, Medical University of Vienna</institution>, <addr-line><named-content content-type="city">Vienna</named-content></addr-line>, <country>Austria</country></aff><aff id="aff5"><institution content-type="dept">Department of Biotechnology</institution>, <institution>University of Natural Resources and Life Sciences, Vienna</institution>, <addr-line><named-content content-type="city">Vienna</named-content></addr-line>, <country>Austria</country></aff><aff id="aff6"><institution content-type="dept">Department of Obstetrics and Gynecology</institution>, <institution>Department of Obstetrics and Gynecology, Medical University of Vienna</institution>, <addr-line><named-content content-type="city">Vienna</named-content></addr-line>, <country>Austria</country></aff><aff id="aff7"><institution content-type="dept">Structural Bioinformatics Laboratory, Biochemistry, Faculty of Science and Engineering</institution>, <institution>Structural Bioinformatics Laboratory, Biochemistry, Faculty of Science and Engineering, Åbo Akademi University</institution>, <addr-line><named-content content-type="city">Turku</named-content></addr-line>, <country>Finland</country></aff><aff id="aff8"><institution content-type="dept">Department of Obstetrics and Gynecology</institution>, <institution>Medical University of Vienna</institution>, <addr-line><named-content content-type="city">Vienna</named-content></addr-line>, <country>Austria</country></aff><aff id="aff9"><institution content-type="dept">Department of Biotechnology</institution>, <institution>Department of Biotechnology, University of Natural Resources and Life Sciences</institution>, <addr-line><named-content content-type="city">Vienna</named-content></addr-line>, <country>Austria</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-149979"><name><surname>Mangoni</surname><given-names>Arduino A</given-names></name><role>Reviewing editor</role><aff><institution>Flinders Medical Centre</institution>, <country>Australia</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>thomas.boehm@meduniwien.ac.at</email> (TB);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>03</day><month>09</month><year>2021</year></pub-date><volume>10</volume><elocation-id>e68542</elocation-id><history><date date-type="received"><day>18</day><month>03</month><year>2021</year></date><date date-type="accepted"><day>01</day><month>09</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Gludovacz et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Gludovacz et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-68542-v1.pdf"/><abstract><p><bold>Background:</bold> Excessive plasma histamine concentrations cause symptoms in mast cell activation syndrome, mastocytosis or anaphylaxis. Anti-histamines are often insufficiently efficacious. Human diamine oxidase (hDAO) can rapidly degrade histamine and therefore represents a promising new treatment strategy for conditions with pathological histamine concentrations.</p><p> <bold>Results:</bold> Recombinant hDAO is rapidly cleared from the circulation in rats and mice. After replacement of positively charged amino acids of the heparin-binding motif with polar serine or threonine residues binding to heparin and heparan sulfate was strongly reduced. The double mutant rhDAO-R568S/R571T showed minimal cellular uptake. The short α-distribution half-life of the wildtype protein was eliminated and the clearance was significantly reduced in rodents.</p><p> <bold>Conclusions: </bold>The successful decrease in plasma clearance of rhDAO by mutations of the heparin-binding motif with unchanged histamine-degrading activity represents the first step towards the development of rhDAO as a first-in-class biopharmaceutical to effectively treat diseases characterized by excessive histamine concentrations in plasma and tissues.</p><p> <bold>Funding: </bold>Austrian Science Fund (FWF) Hertha Firnberg program grant T1135 (EG); ADD funding Sigrid Juselius Foundation, Medicinska Understödsförening Liv och Hälsa rft (TAS and SeV).</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd><kwd>Rat</kwd><kwd>Other</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002428</institution-id><institution>Austrian Science Fund</institution></institution-wrap></funding-source><award-id>T1135</award-id><principal-award-recipient><name><surname>Gludovacz</surname><given-names>Elisabeth</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100006306</institution-id><institution>Sigrid Juséliuksen Säätiö</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Vakal</surname><given-names>Serhii</given-names></name><name><surname>Salminen</surname><given-names>Tiina A</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010116</institution-id><institution>Medicinska Understödsföreningen Liv och Hälsa</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Vakal</surname><given-names>Serhii</given-names></name><name><surname>Salminen</surname><given-names>Tiina A</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Elisabeth Gludovacz, is named as an inventor with The Medical University of Vienna and the University of Natural Resources and Life Sciences of a patent describing the rhDAO heparin-binding motif mutants presented herein (patent pending WO2020169577A1).</p></fn><fn fn-type="conflict" id="conf3"><p>Bernd Jilma, is named as an inventor with The Medical University of Vienna and the University of Natural Resources and Life Sciences of a patent describing the rhDAO heparin-binding motif mutants presented herein (patent pending WO2020169577A1)..</p></fn><fn fn-type="conflict" id="conf4"><p>Nicole Borth, is named as an inventor with The Medical University of Vienna and the University of Natural Resources and Life Sciences of a patent describing the rhDAO heparin-binding motif mutants presented herein (patent pending WO2020169577A1)..</p></fn><fn fn-type="conflict" id="conf5"><p>Thomas Boehm, is named as an inventor with The Medical University of Vienna and the University of Natural Resources and Life Sciences of a patent describing the rhDAO heparin-binding motif mutants presented herein (patent pending WO2020169577A1)..</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: The experimental protocols for the treatment of rats and mice were approved by the local Animal Welfare Committee and the Federal Ministry of Science, Research and Economy (GZ 66.009/0152-WF/V/3b/2014) and conducted in full accordance with the ARRIVE guidelines.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for Figures 2 and 3.</p></sec><supplementary-material><ext-link xlink:href="elife-68542-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>